blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1575477

EP1575477 - HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.03.2013
Database last updated on 02.11.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
CORNELL RESEARCH FOUNDATION, INC.
20 Thornwood Drive, Suite 105
Ithaca, NY 14850 / US
[2012/17]
Former [2005/38]For all designated states
CORNELL RESEARCH FOUNDATION, INC.
20 Thornwood Drive, Suite 105
Ithaca, NY 14850 / US
Inventor(s)01 / HEMPSTEAD, Barbara L.
525 East 86th Street
Apartment 9c
New York, NY 10028 / US
02 / LEE, Ramee
1233 York Avenue, 16E
New York, NY 10021 / US
03 / TENG, Kenneth K.
315 West 86th Street
Apartment 8B
New York, NY 10024 / US
04 / KERMANI, Pouneh
320 East Shore Road
Apartment 12A
Greak Neck, NY 11023 / US
 [2012/17]
Former [2005/38]01 / HEMPSTEAD, Barbara L.
525 East 86th Street, Apartment 9c
New York, NY 10028 / US
02 / LEE, Ramee
1233 York Avenue, 16E
New York, NY 10021 / US
03 / TENG, Kenneth K.
315 West 86th Street, Apartment 8B
New York, NY 10024 / US
04 / KERMANI, Pouneh
320 East Shore Road, Apartment 12A
Greak Neck, NY 11023 / US
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstrasse 4
80802 München / DE
[N/P]
Former [2012/17]Grünecker, Kinkeldey, Stockmair & Schwanhäusser
Anwaltssozietät
Leopoldstrasse 4
80802 München / DE
Former [2005/38]Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
Maximilianstrasse 58
80538 München / DE
Application number, filing date02729305.924.05.2002
[2005/38]
WO2002US16540
Priority number, dateUS20010293823P25.05.2001         Original published format: US 293823 P
US20010305510P13.07.2001         Original published format: US 305510 P
[2005/38]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO02096356
Date:05.12.2002
Language:EN
[2002/49]
Type: A2 Application without search report 
No.:EP1575477
Date:21.09.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 05.12.2002 takes the place of the publication of the European patent application.
[2005/38]
Type: B1 Patent specification 
No.:EP1575477
Date:25.04.2012
Language:EN
[2012/17]
Search report(s)International search report - published on:US18.05.2006
(Supplementary) European search report - dispatched on:EP06.10.2006
ClassificationIPC:A61K38/07, A61K38/08, A61K38/10, A61K38/12, A61K38/48, A61K38/55
[2011/29]
CPC:
C07K14/475 (EP,US); A61K31/4045 (EP,US); A61K31/553 (EP,US);
A61K38/08 (EP,US); A61K38/185 (EP,US); A61K38/482 (EP,US);
A61K38/484 (EP,US); A61K38/4886 (EP,US); A61K38/55 (EP,US);
A61K45/06 (EP,US); A61P19/00 (EP); A61P25/00 (EP);
A61P25/28 (EP); A61P31/04 (EP); A61P31/12 (EP);
A61P35/00 (EP); A61P43/00 (EP); A61P9/10 (EP) (-)
C-Set:
A61K31/4045, A61K2300/00 (US,EP);
A61K31/553, A61K2300/00 (US,EP);
A61K38/08, A61K2300/00 (EP,US)
Former IPC [2006/33]C07K14/00, A01N37/18, A01N61/00, C12N15/00
Former IPC [2005/38]A61K6/00
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2005/38]
TitleGerman:HOCHAFFINER LIGAND FÜR p75 NEUROTROPHIN-REZEPTOR[2005/38]
English:HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR[2005/38]
French:LIGAND A FORTE AFFINITE POUR LE RECEPTEUR DE LA NEUROTROPHINE p75[2005/38]
Entry into regional phase29.12.2003National basic fee paid 
29.12.2003Search fee paid 
29.12.2003Designation fee(s) paid 
29.12.2003Examination fee paid 
Examination procedure29.10.2002Request for preliminary examination filed
International Preliminary Examining Authority: US
29.12.2003Amendment by applicant (claims and/or description)
29.12.2003Examination requested  [2005/38]
14.05.2008Despatch of a communication from the examining division (Time limit: M04)
24.09.2008Reply to a communication from the examining division
21.08.2009Despatch of a communication from the examining division (Time limit: M06)
01.03.2010Reply to a communication from the examining division
22.03.2010Despatch of a communication from the examining division (Time limit: M06)
24.09.2010Reply to a communication from the examining division
31.01.2011Despatch of a communication from the examining division (Time limit: M04)
09.06.2011Reply to a communication from the examining division
24.11.2011Communication of intention to grant the patent
08.03.2012Fee for grant paid
08.03.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.05.2008
Opposition(s)28.01.2013No opposition filed within time limit [2013/14]
Fees paidRenewal fee
28.05.2004Renewal fee patent year 03
30.05.2005Renewal fee patent year 04
30.05.2006Renewal fee patent year 05
30.05.2007Renewal fee patent year 06
28.05.2008Renewal fee patent year 07
27.05.2009Renewal fee patent year 08
25.05.2010Renewal fee patent year 09
25.05.2011Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
IT25.04.2012
NL25.04.2012
SE25.04.2012
TR25.04.2012
IE24.05.2012
LU24.05.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
FR25.06.2012
GR26.07.2012
ES05.08.2012
PT27.08.2012
DE01.12.2012
[2014/27]
Former [2014/21]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
IT25.04.2012
NL25.04.2012
SE25.04.2012
TR25.04.2012
IE24.05.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
FR25.06.2012
GR26.07.2012
ES05.08.2012
PT27.08.2012
DE01.12.2012
Former [2013/30]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
IT25.04.2012
NL25.04.2012
SE25.04.2012
IE24.05.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
FR25.06.2012
GR26.07.2012
ES05.08.2012
PT27.08.2012
DE01.12.2012
Former [2013/23]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
IT25.04.2012
NL25.04.2012
SE25.04.2012
IE24.05.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
FR25.06.2012
GR26.07.2012
ES05.08.2012
PT27.08.2012
Former [2013/22]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
IT25.04.2012
NL25.04.2012
SE25.04.2012
IE24.05.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
GR26.07.2012
ES05.08.2012
PT27.08.2012
Former [2013/20]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
IT25.04.2012
NL25.04.2012
SE25.04.2012
IE24.05.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
GR26.07.2012
PT27.08.2012
Former [2013/11]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
IT25.04.2012
NL25.04.2012
SE25.04.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
GR26.07.2012
PT27.08.2012
Former [2013/08]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
NL25.04.2012
SE25.04.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
GR26.07.2012
PT27.08.2012
Former [2013/07]AT25.04.2012
BE25.04.2012
CY25.04.2012
FI25.04.2012
SE25.04.2012
CH31.05.2012
LI31.05.2012
MC31.05.2012
GR26.07.2012
PT27.08.2012
Former [2013/04]BE25.04.2012
CY25.04.2012
FI25.04.2012
SE25.04.2012
MC31.05.2012
GR26.07.2012
PT27.08.2012
Former [2013/03]CY25.04.2012
FI25.04.2012
SE25.04.2012
MC31.05.2012
GR26.07.2012
PT27.08.2012
Former [2013/01]CY25.04.2012
FI25.04.2012
SE25.04.2012
GR26.07.2012
PT27.08.2012
Former [2012/50]CY25.04.2012
FI25.04.2012
SE25.04.2012
GR26.07.2012
Former [2012/49]CY25.04.2012
FI25.04.2012
SE25.04.2012
Former [2012/48]FI25.04.2012
SE25.04.2012
Documents cited:Search[X]WO9736607  (UNIV CALIFORNIA [US]) [X] 1-57 * example 5; claims 18-33 *;
 [X]WO0075278  (UNIV COLUMBIA [US], et al) [X] 1-57 * page 7, line 24 - line 38; claims 105-130 *;
 [PX]WO0152843  (UNIV MCGILL [CA], et al) [PX] 1 * page 47; claim 10; table 10 *;
 [X]  - CORTAZZO MH ET AL., "Nerve Growth Factor (NGF)-Mediated Protection of Neural Crest Cells from Antimitotic Agent-Induced Apoptosis: The Role of the Low-Affinity NGF Receptor", THE JOURNAL OF NEUROSCIENCE, (19960615), vol. 16, no. 12, ISSN 0270-6474, pages 3895 - 3899, XP002400288 [X] 1-57 * the entire document, particulary page 3897, right-hand column, figure 3 and discussion *
 [X]  - GENTRY JJ ET AL., "Nerve Growth Factor Activation of Nuclear Factor .kappa.B through Its p75 Receptor Is an Anti-apoptotic Signal in RN22 Schwannoma Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20000317), vol. 275, no. 11, ISSN 0021-9258, pages 7558 - 7565, XP002400289 [X] 1-57 * the entire document, particularly page 7562, left-hand column, figure 6 and abstract *

DOI:   http://dx.doi.org/10.1074/jbc.275.11.7558
 [X]  - SOILU-HAENNINEN M ET AL, "Nerve growth factor signaling through p75 induces apoptosis in Schwann cells via a Bcl-2-independent pathway", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, (19990615), vol. 19, no. 12, ISSN 0270-6474, pages 4828 - 4838, XP002234198 [X] 1-57 * the entire document, particularly the discussion *
 [T]  - NYKJAER A ET AL, "Sortilin is essential for proNGF-induced neuronal cell death", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, (20040226), vol. 427, ISSN 0028-0836, pages 843 - 848, XP002286438 [T] * the whole document *

DOI:   http://dx.doi.org/10.1038/nature02319
International search[X]US5288622  (GRAY ALANE M [US], et al);
 [X]  - REINSHAGEN ET AL, J NEUROSCI METHODS., (19970905), vol. 76, no. 1, pages 75 - 81, XP002996303

DOI:   http://dx.doi.org/10.1016/S0165-0270(97)00082-4
 [X]  - MIZUSHIMA ET AL, ONCOLOGY., (1984), vol. 41, pages 289 - 292, XP008062586
 [X]  - ROWINSKY ET AL, "Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies", J CLIN ONCOL., (200001), vol. 18, no. 1, pages 178 - 186, XP003003463
 [Y]  - FOTOUCHI ET AL, J BIOL CHEM., (199412), vol. 269, no. 48, pages 30227 - 30231, XP002996305
 [X]  - EVANS ET AL, CLIN CANCER RES., (199911), vol. 5, no. 11, pages 3594 - 3602, XP002996306
 [Y]  - AKINAGA ET AL, "Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor k-252a, and its mechanism of action", CANCER CHEMOTHER PHARMACOL., (1992), vol. 29, no. 4, pages 266 - 272, XP002104872

DOI:   http://dx.doi.org/10.1007/BF00685943
 [Y]  - BRANN ET AL, J NEUROSCI., (199910), vol. 19, no. 19, pages 8199 - 8206, XP002996307
 [P]  - FAHNESTOCK ET AL, "The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease", MOL CELL NEUROSCI., (2001), vol. 18, no. 2, pages 210 - 220, XP002294169

DOI:   http://dx.doi.org/10.1006/mcne.2001.1016
 [P]  - CHEN ET AL, "CHARACTERIZATION OF NERVE GROWTH FACTOR PRECURSOR PROTEIN EXPRESSION IN RAT ROUND SPERMATIDS AND THE TROPHIC EFFECTS OF NERVEGROWTH FACTOR IN THE MAINTENANCE OF SERTOLI CELL VIABILITY", MOL CELL ENDOCRINOL., (1997), vol. 127, no. 2, pages 129 - 136, XP001005638

DOI:   http://dx.doi.org/10.1016/S0303-7207(96)04001-4
 [P]  - BARKER P A., NEURON., (2004), vol. 42, pages 529 - 533, XP002996308

DOI:   http://dx.doi.org/10.1016/j.neuron.2004.04.001
 [P]  - FRADE ET AL, "INDUCTION OF CELL DEATH BY ENDOGENOUS NERVE GROWTH FACTOR THROUGH ITS P75 RECEPTOR", NATURE., (19960912), vol. 383, no. 6596, pages 166 - 168, XP002914976

DOI:   http://dx.doi.org/10.1038/383166a0
Examination   - LEE R ET AL, Regulation of Cell Survival by Secreted Proneurotrophins, SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, PAGE(S) 1945 - 1948, (20011130), ISSN 0036-8075, XP003002960

DOI:   http://dx.doi.org/10.1126/science.1065057
by applicant   - GEORGE, D.G. ET AL., Macromolecular Sequencing and Synthesis, Selected Methods and Applications, ALAN R. LISS, INC., (1988), pages 127 - 149
    - ANES. ANAL., (2001), vol. 92, page 775
    - ANN THORAC. SURG., (2000), vol. 70, page 1300
    - Gene Expression Technology, Methods in Enzymology, ACADEMIC PRESS, INC., (1991), vol. 185
    - "Methods in Molecular Biology", Gene Transfer and Expression Protocols, THE HUMANA PRESS INC., (1991), vol. 7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.